Industries > Pharma > Global Neuromodulation Devices Report 2020-2030

Global Neuromodulation Devices Report 2020-2030

Deep Brain Stimulation (DBS), Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Sacral Nerve Stimulation (SNS), Gastric Electrical Stimulation (GES), Other Applications and leading companies analysis in Neuromodulation Devices

PUBLISHED: 30 April 2020
PAGES: 238
PRODUCT CODE: PHA0715

Clear
WOOCS 2.2.1

The neuromodulation devices market is estimated to grow at a CAGR of 12.1% over the forecast period.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 238-page report you will receive 130 charts– all unavailable elsewhere.

The 238-page report provides clear detailed insight into the global neuromodulation devices market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Neuromodulation Devices market forecasts from 2020-2030

• This report also breaks down the revenue forecast for the global neuromodulation devices market by type:
• Deep Brain Stimulation (DBS), Spinal Cord Stimulation (SCS)
• Vagus Nerve Stimulation (VNS)
• Sacral Nerve Stimulation (SNS)
• Gastric Electrical Stimulation (GES)
• Other Applications

This report discusses the market trends and lists the leading products/pipeline products of each submarket.

• This report provides individual revenue forecasts to 2030 for these regional and national markets:
• North America: the US and Canada
• Europe: France, Germany, Italy, U.K, Spain, Russia, Netherlands, Switzerland, Belgium, Austria, Rest of Europe
• Asia-Pacific: Japan, China, India, Australia, South Korea and rest of Asia-Pacific
• Latin America: Brazil, Mexico, Argentina, Rest of Latin America
• Rest of the World: Middle East, Africa

Global Neuromodulation Devices Report 2020-2030

Each regional market is further segmented by type of applications: Deep Brain Stimulation (DBS), Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Sacral Nerve Stimulation (SNS), Gastric Electrical Stimulation (GES), Other Applications

• Our study gives qualitative analysis of the neuromodulation devices market. It discusses the factors that drive and restrain the neuromodulation devices market. This study also provides a SWOT and STEP analysis.

• Our study discusses the selected leading companies that are the major players in the neuromodulation devices industry:
• Medtronic
• Boston Scientific
• Abbott Laboratories
• LivaNova PLC
• & Other Companies

Visiongain’s study is intended for anyone requiring commercial analyses for the global neuromodulation devices market. You find data, trends and predictions.

Buy our report today Global Neuromodulation Devices Report 2020-2030: Deep Brain Stimulation (DBS), Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Sacral Nerve Stimulation (SNS), Gastric Electrical Stimulation (GES), Other Applications.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Global Neuromodulation Devices Report 2020-2030


Download sample pages

Complete the form below to download your free sample pages for Global Neuromodulation Devices Report 2020-2030


Latest Pharma news

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

READ

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

READ

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

READ

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

READ

Categories

Category